[Certain problems of therapy with beta-interferon preparations].
The latest data on clinical effects of beta-interferon-1b (betaferon) in different clinical types of multile sclerosis (MS) are discussed in this review. All local and systemic side effects of this treatment are discussed as well as possible influence of neutralizing antibodies (NAB) on clinical efficacy of this treatment. Moderate and easily treated side effects as well as the absence of significant evidence for modulation of positive clinical effects of beta-interferons by NAT allow one to consider this medicine as one of the basic methods of MS treatment.
Gusev
E I
EI
Demina
T L
TL
Boĭko
A N
AN
Khachanova
N V
NV
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use; D003865:Major Depressive Disorder / Q000188:drug therapy / Q000209:etiology; D015673:Fatigue Syndrome, Chronic / Q000209:etiology; D005260:Female; D006801:Humans; D016899:Interferon-beta / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000523:psychology*
D000276:Adjuvants, Immunologic; D000928:Antidepressive Agents; D016899:Interferon-beta